arrow_back Back to App

US Support for Global Alzheimer's Fight

This act authorizes the United States to participate in the Davos Alzheimer’s Collaborative (DAC), an international initiative. The goal is to accelerate research, diagnosis, and treatment of Alzheimer's disease globally, which could also benefit American patients and their families. These efforts aim to reduce the financial and social burden associated with the disease.
Key points
The U.S. will join global cooperative efforts to combat Alzheimer's disease, including in low- and middle-income countries.
U.S. financial contributions to DAC will be contingent on securing funding from other sources, capped at 33% of total contributions.
The act aims to develop diagnostics and treatments for diverse populations, including minorities disproportionately affected by the disease.
Women, who are more frequently affected and are primary caregivers, may particularly benefit from advancements in research and care.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_3674
Sponsor: Rep. Bera, Ami [D-CA-6]
Process start date: 2025-06-03
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Global Alzheimer’s Initiative Now Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_3674.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-06-03.

What are the main provisions?

Key points include:

  • The U.S. will join global cooperative efforts to combat Alzheimer's disease, including in low- and middle-income countries.
  • U.S. financial contributions to DAC will be contingent on securing funding from other sources, capped at 33% of total contributions.
  • The act aims to develop diagnostics and treatments for diverse populations, including minorities disproportionately affected by the disease.
  • Women, who are more frequently affected and are primary caregivers, may particularly benefit from advancements in research and care.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Bera, Ami [D-CA-6].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Foreign Affairs.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health Public Investments